The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer.

Autor: Butter R; Department of Pathology, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, The Netherlands., Hondelink LM; Department of Pathology, Leiden University Medical Center, Leiden University, The Netherlands., van Elswijk L; Independent Operating Psychologist, The Netherlands., Blaauwgeers JLG; Department of Pathology, OLVG LAB BV, Amsterdam, The Netherlands., Bloemena E; Department of Pathology, Amsterdam University Medical Centers, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, The Netherlands., Britstra R; Department of Pathology, Amsterdam University Medical Centers, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, The Netherlands., Bulkmans N; Department of Pathology, Spaarne Gasthuis, Haarlem, The Netherlands., van Gulik AL; Department of Pathology, University Hospital Cologne, Germany., Monkhorst K; Department of Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., de Rooij MJ; Department of Pathology, Symbiant Pathology Expert Center, Alkmaar, The Netherlands., Slavujevic-Letic I; Department of Pathology, Symbiant Pathology Expert Center, Alkmaar, The Netherlands., Smit VTHBM; Department of Pathology, Leiden University Medical Center, Leiden University, The Netherlands., Speel EM; Department of Pathology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, University of Maastricht, The Netherlands., Thunnissen E; Department of Pathology, Amsterdam University Medical Centers, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, The Netherlands., von der Thüsen JH; Department of Pathology, Erasmus University Medical Center, Erasmus University Rotterdam, The Netherlands., Timens W; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, The Netherlands., van de Vijver MJ; Department of Pathology, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, The Netherlands., Yick DCY; Department of Pathology, Amphia Hospital, Breda, The Netherlands., Zwinderman AH; Department of Clinical Epidemiology and Biostatistics, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands., Cohen D; Department of Pathology, Leiden University Medical Center, Leiden University, The Netherlands., 't Hart NA; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, The Netherlands; Department of Pathology, Isala Hospitals, Zwolle, The Netherlands., Radonic T; Department of Pathology, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, The Netherlands; Department of Pathology, Amsterdam University Medical Centers, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, The Netherlands. Electronic address: t.radonic@amsterdamumc.nl.

Publikováno v: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2022 Apr; Vol. 166, pp. 143-149. Date of Electronic Publication: 2022 Mar 05.

Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.

Autor: Theelen WSME; Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kuilman T; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Schulze K; Oncology Biomarker Development, Genentech Inc., South San Francisco, United States of America., Zou W; Biostatistics, Genentech Inc., South San Francisco, United States of America., Krijgsman O; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Peters DDGC; Core Facility Molecular Pathology & Biobanking, Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Cornelissen S; Core Facility Molecular Pathology & Biobanking, Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Monkhorst K; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Sarma P; Oncology Biomarker Development, Genentech Inc., South San Francisco, United States of America., Sumiyoshi T; Oncology Biomarker Development, Genentech Inc., South San Francisco, United States of America., Amler LC; Oncology Biomarker Development, Genentech Inc., South San Francisco, United States of America., Willems SM; Department of Pathology, University Medical Centre Utrecht, Utrecht, The Netherlands., Blaauwgeers JLG; Department of Pathology, OLVG, Amsterdam, The Netherlands., van Noesel CJM; Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands., Peeper DS; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Heuvel MM; Department of Pulmonology, Radboud University Medical Center, Nijmegen, The Netherlands., Kowanetz M; Oncology Biomarker Development, Genentech Inc., South San Francisco, United States of America.

Publikováno v: PloS one [PLoS One] 2019 May 24; Vol. 14 (5), pp. e0216864. Date of Electronic Publication: 2019 May 24 (Print Publication: 2019).